ConductScience.org, home

Paper6966652

In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors.

Yron I and 3 others. J Immunol, 1980. Cited by 262 papers, by iCite.

Cite this record

ConductScience Library. In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors. Papers, record 6966652. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6966652

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors.
PubMed
Journal
J Immunol
PubMed
Year
1980
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
262
iCite
Relative citation ratio, by iCite
5.29
iCite
Revised in PubMed
2003-11-14
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Yron II
2Wood TA JrT A
3Spiess PJP J
4Rosenberg SAS A

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Cell Transformation, NeoplasticMajor topic
Sarcoma, ExperimentalMajor topic
T-LymphocytesMajor topic
Animals
Cell Division
Cell Separation
Cells, Cultured
Cytotoxicity, Immunologic
Female
Growth Substances
Histiocytes
Lymphocytes
Mice
Mice, Inbred C57BL

Source PubMed

Download CSV of topics

Cited by57

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 262 citations.

PMIDTitleJournalYearIn PapersSource
42272961Adoptive T-cell therapies in the clinic.Bioeng Transl Med2026https://conductscience.org/library/papers/42272961PubMed
42099873Advances in cell therapy for solid tumours: European perspective and future directions.Lancet Reg Health Eur2026https://conductscience.org/library/papers/42099873PubMed
41058692Recent advances in adoptive cell therapy for cancer immunotherapy.Front Immunol2025https://conductscience.org/library/papers/41058692PubMed
40765841Tumour-infiltrating lymphocyte therapy landscape: prospects and challenges.BMJ Oncol2025https://conductscience.org/library/papers/40765841PubMed
39129675Clinical protocol phase II study of tumor infiltrating lymphocytes in advanced tumors with alterations in the SWI/SNF complex: the TILTS study.Future Oncol2024https://conductscience.org/library/papers/39129675PubMed
39012213Lifileucel: FDA-approved T-cell therapy for melanoma.Oncologist2024https://conductscience.org/library/papers/39012213PubMed
38666543Developing innovative strategies of tumor‑infiltrating lymphocyte therapy for tumor treatment.Oncol Rep2024https://conductscience.org/library/papers/38666543PubMed
38503296FDA approval of the first cellular therapy for a solid (non-hematologic) cancer.Mol Ther2024https://conductscience.org/library/papers/38503296PubMed
37345057Recent Advances in Molecular Mechanisms of Cancer Immunotherapy.Cancers (Basel)2023https://conductscience.org/library/papers/37345057PubMed
34140957Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer.Front Immunol2021https://conductscience.org/library/papers/34140957PubMed
34134616Immersion in the search for effective cancer immunotherapies.Mol Med2021https://conductscience.org/library/papers/34134616PubMed
33335718Cancer T-cell therapy: building the foundation for a cure.F1000Res2020https://conductscience.org/library/papers/33335718PubMed
32975147Chimeric antigen receptor T cell therapy for pediatric and young adult B cell acute lymphoblastic leukemia.Expert Rev Clin Immunol2020https://conductscience.org/library/papers/32975147PubMed
32879472Human immunology and immunotherapy: main achievements and challenges.Cell Mol Immunol2021https://conductscience.org/library/papers/32879472PubMed
32612154The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications.Cell Mol Immunol2020https://conductscience.org/library/papers/32612154PubMed
29700396A history of exploring cancer in context.Nat Rev Cancer2018https://conductscience.org/library/papers/29700396PubMed
29456568Harnessing the immune system in the battle against breast cancer.Drugs Context2018https://conductscience.org/library/papers/29456568PubMed
29443657IL-2 and Beyond in Cancer Immunotherapy.J Interferon Cytokine Res2018https://conductscience.org/library/papers/29443657PubMed
28729866Cytokine-Induced Killer Cells As Pharmacological Tools for Cancer Immunotherapy.Front Immunol2017https://conductscience.org/library/papers/28729866PubMed
26037048The Past, Present, and Future of NK Cells in Hematopoietic Cell Transplantation and Adoptive Transfer.Curr Top Microbiol Immunol2016https://conductscience.org/library/papers/26037048PubMed

See all 57 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/6966652

GET https://conductscience.org/api/papers/v1/6966652/cited_by?page=2